215 related articles for article (PubMed ID: 26437728)
1. Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy.
Jordan SJ; Wilson LF; Nagle CM; Green AC; Olsen CM; Bain CJ; Pandeya N; Whiteman DC; Webb PM
Aust N Z J Public Health; 2015 Oct; 39(5):434-40. PubMed ID: 26437728
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
3. Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives.
Jordan SJ; Wilson LF; Nagle CM; Green AC; Olsen CM; Bain CJ; Pandeya N; Whiteman DC; Webb PM
Aust N Z J Public Health; 2015 Oct; 39(5):441-5. PubMed ID: 26437729
[TBL] [Abstract][Full Text] [Related]
4. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
5. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies.
Pfeiffer RM; Park Y; Kreimer AR; Lacey JV; Pee D; Greenlee RT; Buys SS; Hollenbeck A; Rosner B; Gail MH; Hartge P
PLoS Med; 2013; 10(7):e1001492. PubMed ID: 23935463
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
7. [Drugs and cancer risk: the example of THM].
Fournier A; Hill C
Rev Prat; 2013 Oct; 63(8):1117-21. PubMed ID: 24298831
[TBL] [Abstract][Full Text] [Related]
8. The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.
Laaksonen MA; Arriaga ME; Canfell K; MacInnis RJ; Byles JE; Banks E; Shaw JE; Mitchell P; Giles GG; Magliano DJ; Gill TK; Klaes E; Velentzis LS; Hirani V; Cumming RG; Vajdic CM
Gynecol Oncol; 2019 Jun; 153(3):580-588. PubMed ID: 30935715
[TBL] [Abstract][Full Text] [Related]
9. [Menopausal hormonal therapy and cancer risks].
Lasserre A; Fournier A
Gynecol Obstet Fertil; 2016; 44(7-8):424-7. PubMed ID: 27451070
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cancers of the breast, endometrium and ovary.
Pike MC; Pearce CL; Wu AH
Oncogene; 2004 Aug; 23(38):6379-91. PubMed ID: 15322512
[TBL] [Abstract][Full Text] [Related]
11. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
12. The prevention of breast cancer through reduced ovarian steroid exposure.
Spicer DV; Pike MC
Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
[TBL] [Abstract][Full Text] [Related]
13. Cancers in Australia in 2010 attributable to total breastfeeding durations of 12 months or less by parous women.
Jordan SJ; Wilson LF; Nagle CM; Green AC; Olsen CM; Bain CJ; Pandeya N; Whiteman DC; Webb PM
Aust N Z J Public Health; 2015 Oct; 39(5):418-21. PubMed ID: 26437725
[TBL] [Abstract][Full Text] [Related]
14. Cancers in Australia in 2010 attributable to overweight and obesity.
Kendall BJ; Wilson LF; Olsen CM; Webb PM; Neale RE; Bain CJ; Whiteman DC
Aust N Z J Public Health; 2015 Oct; 39(5):452-7. PubMed ID: 26437731
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and breast cancer.
Santen RJ
J Steroid Biochem Mol Biol; 2014 Jul; 142():52-61. PubMed ID: 23871991
[TBL] [Abstract][Full Text] [Related]
16. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
[TBL] [Abstract][Full Text] [Related]
17. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones ME; Schoemaker MJ; Wright L; McFadden E; Griffin J; Thomas D; Hemming J; Wright K; Ashworth A; Swerdlow AJ
Br J Cancer; 2016 Aug; 115(5):607-15. PubMed ID: 27467055
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
[TBL] [Abstract][Full Text] [Related]
19. The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review.
Eden J
Aust N Z J Obstet Gynaecol; 2017 Feb; 57(1):12-15. PubMed ID: 28251642
[TBL] [Abstract][Full Text] [Related]
20. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?
Rozenberg S; Antoine C; Vandromme J; Fastrez M
Climacteric; 2015; 18(4):448-52. PubMed ID: 25958744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
